Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer
esmo - Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study
AI Summary: A randomized first‑line trial found that adding retifanlimab to standard chemotherapy meaningfully improved overall survival for patients with advanced squamous anal cancer, signaling a new immunotherapy-containing option where few exist. The data from the POD1UM‑303/InterAACT‑2 program offer clinicians a viable strategy to extend life without reinventing the wheel.
Kicking Off the Cancer Planners Forum in Geneva – UICC
oncodaily - Union for International Cancer Control (UICC) shared a post on LinkedIn: “We’re excited to kick off the Cancer Planners Forum in Geneva today! Convening national leaders responsible for cancer control planning, […]
AI Summary: The UICC Cancer Planners Forum in Geneva brought policymakers, clinicians, and public‑health leaders together to map national cancer control strategies, prioritize cervical cancer elimination, and foster implementation partnerships. The forum emphasized practical planning, stakeholder engagement, and resource‑sensitive solutions to turn plans into measurable improvements in prevention, screening, and care delivery.
- Cervical cancer elimination and clinical partnerships (3)
- Forum launch and wrap-up in Geneva (3)
- National cancer planning and policy priorities (3)
- All Other Stories
Cervical cancer elimination and clinical partnerships
Forum launch and wrap-up in Geneva
National cancer planning and policy priorities
All Other Stories
OLIGOMA Trial: SBRT Extends PFS in Oligometastatic Breast Cancer
oncodaily - The OLIGOMA trial presented at ESTRO 2026 brings new attention to one of the most debated questions in metastatic breast cancer: can treating limited metastatic sites with stereotactic body radiotherapy […]
AI Summary: A randomized trial shows stereotactic body radiotherapy (SBRT) targeting limited metastatic breast lesions prolongs progression‑free survival, offering longer disease control for selected patients with oligometastatic disease. Toxicity was manageable, suggesting SBRT could become a pragmatic, tissue‑sparing option to delay systemic therapy escalation.
- ESTRO reaction: clinicians and advocates amplify SBRT findings (3)
- EXTEND and practice: metastasis-directed therapy, guidelines, and AI (4)
- OLIGOMA: SBRT extends PFS in oligometastatic breast cancer (3)
- All Other Stories
ESTRO reaction: clinicians and advocates amplify SBRT findings
EXTEND and practice: metastasis-directed therapy, guidelines, and AI
OLIGOMA: SBRT extends PFS in oligometastatic breast cancer
All Other Stories
Overactive MYC helps tumors fix DNA breaks and resist chemotherapy, study finds
medicalxpress - A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.
AI Summary: New research reveals overactive MYC drives tumor cells to repair DNA breaks more efficiently, enabling resistance to chemotherapy. By illuminating the repair pathways MYC hijacks, the study identifies potential targets to reverse resistance and improve treatment responses — because apparently cancers read the manual on how to survive your best shot.
- MYC hijacks DNA repair to enable chemo resistance (4)
- Other molecular drivers of chemoresistance and genome instability (3)
- Tumor cell death and immunity shape chemotherapy outcomes (3)
- All Other Stories